nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Thalidomide—leprosy	0.177	0.263	CbGbCtD
Bexarotene—CYP2C9—Rifampicin—leprosy	0.171	0.255	CbGbCtD
Bexarotene—CYP2C9—Dapsone—leprosy	0.141	0.211	CbGbCtD
Bexarotene—CYP3A4—Rifampicin—leprosy	0.0995	0.148	CbGbCtD
Bexarotene—CYP3A4—Dapsone—leprosy	0.0822	0.122	CbGbCtD
Bexarotene—Lacrimal structural disorder—Thalidomide—leprosy	0.00667	0.0203	CcSEcCtD
Bexarotene—Hypoproteinaemia—Thalidomide—leprosy	0.00667	0.0203	CcSEcCtD
Bexarotene—Lipase increased—Thalidomide—leprosy	0.00667	0.0203	CcSEcCtD
Bexarotene—Circumoral paresthesia—Thalidomide—leprosy	0.00601	0.0183	CcSEcCtD
Bexarotene—Albuminuria—Dapsone—leprosy	0.00513	0.0156	CcSEcCtD
Bexarotene—Hypochromic anaemia—Thalidomide—leprosy	0.00506	0.0154	CcSEcCtD
Bexarotene—Lacrimal disorder—Thalidomide—leprosy	0.00438	0.0133	CcSEcCtD
Bexarotene—Paraesthesia oral—Thalidomide—leprosy	0.00418	0.0127	CcSEcCtD
Bexarotene—Peripheral vascular disorder—Thalidomide—leprosy	0.004	0.0121	CcSEcCtD
Bexarotene—Lactic dehydrogenase activity increased—Thalidomide—leprosy	0.00383	0.0116	CcSEcCtD
Bexarotene—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00337	0.0102	CcSEcCtD
Bexarotene—Febrile neutropenia—Thalidomide—leprosy	0.00326	0.0099	CcSEcCtD
Bexarotene—Enlargement abdomen—Thalidomide—leprosy	0.00326	0.0099	CcSEcCtD
Bexarotene—Myasthenia—Thalidomide—leprosy	0.00312	0.00948	CcSEcCtD
Bexarotene—Psoriasis—Thalidomide—leprosy	0.00312	0.00948	CcSEcCtD
Bexarotene—Hypomagnesaemia—Thalidomide—leprosy	0.00309	0.00938	CcSEcCtD
Bexarotene—Oral candidiasis—Thalidomide—leprosy	0.00309	0.00938	CcSEcCtD
Bexarotene—Hypothyroidism—Thalidomide—leprosy	0.00305	0.00928	CcSEcCtD
Bexarotene—Seborrhoeic dermatitis—Thalidomide—leprosy	0.00288	0.00874	CcSEcCtD
Bexarotene—Hypercalcaemia—Thalidomide—leprosy	0.00282	0.00857	CcSEcCtD
Bexarotene—Lung disorder—Thalidomide—leprosy	0.00277	0.00841	CcSEcCtD
Bexarotene—Nystagmus—Thalidomide—leprosy	0.00274	0.00834	CcSEcCtD
Bexarotene—Hyperlipidaemia—Thalidomide—leprosy	0.00272	0.00826	CcSEcCtD
Bexarotene—Stupor—Thalidomide—leprosy	0.00263	0.00798	CcSEcCtD
Bexarotene—Neuritis—Thalidomide—leprosy	0.00263	0.00798	CcSEcCtD
Bexarotene—Albuminuria—Thalidomide—leprosy	0.00263	0.00798	CcSEcCtD
Bexarotene—Pleural effusion—Thalidomide—leprosy	0.00256	0.00778	CcSEcCtD
Bexarotene—Skin ulcer—Thalidomide—leprosy	0.00252	0.00765	CcSEcCtD
Bexarotene—Hyperaesthesia—Thalidomide—leprosy	0.0025	0.00759	CcSEcCtD
Bexarotene—Rash pustular—Thalidomide—leprosy	0.00246	0.00747	CcSEcCtD
Bexarotene—Muscular weakness—Dapsone—leprosy	0.00245	0.00745	CcSEcCtD
Bexarotene—Influenza—Dapsone—leprosy	0.0024	0.0073	CcSEcCtD
Bexarotene—Petechiae—Thalidomide—leprosy	0.00238	0.00724	CcSEcCtD
Bexarotene—Endocrine disorder—Thalidomide—leprosy	0.00236	0.00718	CcSEcCtD
Bexarotene—Pancreatitis—Dapsone—leprosy	0.00236	0.00716	CcSEcCtD
Bexarotene—Blood disorder—Thalidomide—leprosy	0.00235	0.00713	CcSEcCtD
Bexarotene—Acne—Thalidomide—leprosy	0.00233	0.00708	CcSEcCtD
Bexarotene—Jaundice cholestatic—Thalidomide—leprosy	0.00223	0.00678	CcSEcCtD
Bexarotene—Photosensitivity reaction—Dapsone—leprosy	0.00219	0.00666	CcSEcCtD
Bexarotene—Viral infection—Thalidomide—leprosy	0.00217	0.00659	CcSEcCtD
Bexarotene—Arthropathy—Thalidomide—leprosy	0.00216	0.00655	CcSEcCtD
Bexarotene—Cellulitis—Thalidomide—leprosy	0.00216	0.00655	CcSEcCtD
Bexarotene—Hyperbilirubinaemia—Thalidomide—leprosy	0.00216	0.00655	CcSEcCtD
Bexarotene—Thinking abnormal—Thalidomide—leprosy	0.00214	0.00651	CcSEcCtD
Bexarotene—Hypocalcaemia—Thalidomide—leprosy	0.00214	0.00651	CcSEcCtD
Bexarotene—Herpes simplex—Thalidomide—leprosy	0.00213	0.00646	CcSEcCtD
Bexarotene—Hyperuricaemia—Thalidomide—leprosy	0.00211	0.00642	CcSEcCtD
Bexarotene—Neuropathy peripheral—Dapsone—leprosy	0.0021	0.00638	CcSEcCtD
Bexarotene—Hypercholesterolaemia—Thalidomide—leprosy	0.00207	0.0063	CcSEcCtD
Bexarotene—Creatinine increased—Thalidomide—leprosy	0.00206	0.00626	CcSEcCtD
Bexarotene—Bone pain—Thalidomide—leprosy	0.00205	0.00622	CcSEcCtD
Bexarotene—Sinusitis—Dapsone—leprosy	0.00201	0.00611	CcSEcCtD
Bexarotene—Gait disturbance—Thalidomide—leprosy	0.00201	0.0061	CcSEcCtD
Bexarotene—Blood uric acid increased—Thalidomide—leprosy	0.002	0.00606	CcSEcCtD
Bexarotene—Phosphatase alkaline increased—Thalidomide—leprosy	0.00196	0.00596	CcSEcCtD
Bexarotene—Hepatocellular injury—Thalidomide—leprosy	0.00196	0.00596	CcSEcCtD
Bexarotene—Eructation—Thalidomide—leprosy	0.00193	0.00585	CcSEcCtD
Bexarotene—Hyperkalaemia—Thalidomide—leprosy	0.00193	0.00585	CcSEcCtD
Bexarotene—Pharyngitis—Dapsone—leprosy	0.00191	0.0058	CcSEcCtD
Bexarotene—Depressed level of consciousness—Thalidomide—leprosy	0.00189	0.00575	CcSEcCtD
Bexarotene—Colitis—Thalidomide—leprosy	0.00188	0.00572	CcSEcCtD
Bexarotene—Candida infection—Thalidomide—leprosy	0.00187	0.00569	CcSEcCtD
Bexarotene—Neuropathy—Thalidomide—leprosy	0.00184	0.00559	CcSEcCtD
Bexarotene—Dry eye—Thalidomide—leprosy	0.00181	0.0055	CcSEcCtD
Bexarotene—Cramps of lower extremities—Thalidomide—leprosy	0.0018	0.00547	CcSEcCtD
Bexarotene—Tinnitus—Dapsone—leprosy	0.00179	0.00545	CcSEcCtD
Bexarotene—Rash maculo-papular—Thalidomide—leprosy	0.00178	0.00541	CcSEcCtD
Bexarotene—Pulmonary oedema—Thalidomide—leprosy	0.00174	0.0053	CcSEcCtD
Bexarotene—Hypertonia—Thalidomide—leprosy	0.00172	0.00522	CcSEcCtD
Bexarotene—Mental disability—Thalidomide—leprosy	0.0017	0.00517	CcSEcCtD
Bexarotene—Sepsis—Thalidomide—leprosy	0.0017	0.00517	CcSEcCtD
Bexarotene—Erythema—Dapsone—leprosy	0.00167	0.00509	CcSEcCtD
Bexarotene—Lymphadenopathy—Thalidomide—leprosy	0.00167	0.00507	CcSEcCtD
Bexarotene—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00164	0.00497	CcSEcCtD
Bexarotene—Gastroenteritis—Thalidomide—leprosy	0.00161	0.00488	CcSEcCtD
Bexarotene—Vascular purpura—Thalidomide—leprosy	0.00159	0.00483	CcSEcCtD
Bexarotene—Deafness—Thalidomide—leprosy	0.00159	0.00483	CcSEcCtD
Bexarotene—Eye pain—Thalidomide—leprosy	0.00158	0.00479	CcSEcCtD
Bexarotene—Cardiac failure congestive—Thalidomide—leprosy	0.00157	0.00477	CcSEcCtD
Bexarotene—Libido decreased—Thalidomide—leprosy	0.00153	0.00466	CcSEcCtD
Bexarotene—Increased appetite—Thalidomide—leprosy	0.00151	0.0046	CcSEcCtD
Bexarotene—Dermatitis exfoliative—Thalidomide—leprosy	0.00151	0.00458	CcSEcCtD
Bexarotene—Vertigo—Dapsone—leprosy	0.0015	0.00457	CcSEcCtD
Bexarotene—Dermatitis bullous—Thalidomide—leprosy	0.00149	0.00452	CcSEcCtD
Bexarotene—Purpura—Thalidomide—leprosy	0.00148	0.00449	CcSEcCtD
Bexarotene—Arthritis—Thalidomide—leprosy	0.00146	0.00445	CcSEcCtD
Bexarotene—Cough—Dapsone—leprosy	0.00146	0.00444	CcSEcCtD
Bexarotene—Lethargy—Thalidomide—leprosy	0.00145	0.00441	CcSEcCtD
Bexarotene—Cerebrovascular accident—Thalidomide—leprosy	0.00145	0.00441	CcSEcCtD
Bexarotene—Hyponatraemia—Thalidomide—leprosy	0.00143	0.00434	CcSEcCtD
Bexarotene—Osteoarthritis—Thalidomide—leprosy	0.00142	0.00432	CcSEcCtD
Bexarotene—Disturbance in sexual arousal—Thalidomide—leprosy	0.00141	0.00429	CcSEcCtD
Bexarotene—Affect lability—Thalidomide—leprosy	0.0014	0.00426	CcSEcCtD
Bexarotene—Migraine—Thalidomide—leprosy	0.0014	0.00426	CcSEcCtD
Bexarotene—Face oedema—Thalidomide—leprosy	0.00137	0.00417	CcSEcCtD
Bexarotene—Mood swings—Thalidomide—leprosy	0.00135	0.0041	CcSEcCtD
Bexarotene—Ataxia—Thalidomide—leprosy	0.00134	0.00407	CcSEcCtD
Bexarotene—Tachycardia—Dapsone—leprosy	0.00133	0.00405	CcSEcCtD
Bexarotene—Blood creatinine increased—Thalidomide—leprosy	0.00133	0.00405	CcSEcCtD
Bexarotene—Dehydration—Thalidomide—leprosy	0.00132	0.00402	CcSEcCtD
Bexarotene—Liver function test abnormal—Thalidomide—leprosy	0.00131	0.00399	CcSEcCtD
Bexarotene—Dry skin—Thalidomide—leprosy	0.0013	0.00396	CcSEcCtD
Bexarotene—Hypokalaemia—Thalidomide—leprosy	0.00129	0.00393	CcSEcCtD
Bexarotene—Aspartate aminotransferase increased—Thalidomide—leprosy	0.00128	0.00389	CcSEcCtD
Bexarotene—Alanine aminotransferase increased—Thalidomide—leprosy	0.00125	0.00381	CcSEcCtD
Bexarotene—Muscular weakness—Thalidomide—leprosy	0.00125	0.00381	CcSEcCtD
Bexarotene—Abdominal distension—Thalidomide—leprosy	0.00124	0.00376	CcSEcCtD
Bexarotene—Insomnia—Dapsone—leprosy	0.00124	0.00375	CcSEcCtD
Bexarotene—Influenza—Thalidomide—leprosy	0.00123	0.00374	CcSEcCtD
Bexarotene—Dysphagia—Thalidomide—leprosy	0.00123	0.00374	CcSEcCtD
Bexarotene—Eosinophilia—Thalidomide—leprosy	0.00122	0.0037	CcSEcCtD
Bexarotene—Pancreatitis—Thalidomide—leprosy	0.00121	0.00366	CcSEcCtD
Bexarotene—Angina pectoris—Thalidomide—leprosy	0.0012	0.00364	CcSEcCtD
Bexarotene—Bronchitis—Thalidomide—leprosy	0.00118	0.00359	CcSEcCtD
Bexarotene—Pancytopenia—Thalidomide—leprosy	0.00117	0.00355	CcSEcCtD
Bexarotene—Neutropenia—Thalidomide—leprosy	0.00115	0.00349	CcSEcCtD
Bexarotene—Pollakiuria—Thalidomide—leprosy	0.00114	0.00345	CcSEcCtD
Bexarotene—Erectile dysfunction—Thalidomide—leprosy	0.00113	0.00344	CcSEcCtD
Bexarotene—Photosensitivity reaction—Thalidomide—leprosy	0.00112	0.00341	CcSEcCtD
Bexarotene—Weight increased—Thalidomide—leprosy	0.00112	0.0034	CcSEcCtD
Bexarotene—Gastrointestinal pain—Dapsone—leprosy	0.00112	0.00339	CcSEcCtD
Bexarotene—Weight decreased—Thalidomide—leprosy	0.00111	0.00338	CcSEcCtD
Bexarotene—Hyperglycaemia—Thalidomide—leprosy	0.00111	0.00337	CcSEcCtD
Bexarotene—Pneumonia—Thalidomide—leprosy	0.0011	0.00335	CcSEcCtD
Bexarotene—Body temperature increased—Dapsone—leprosy	0.00108	0.00328	CcSEcCtD
Bexarotene—Abdominal pain—Dapsone—leprosy	0.00108	0.00328	CcSEcCtD
Bexarotene—Neuropathy peripheral—Thalidomide—leprosy	0.00107	0.00327	CcSEcCtD
Bexarotene—Stomatitis—Thalidomide—leprosy	0.00107	0.00325	CcSEcCtD
Bexarotene—Conjunctivitis—Thalidomide—leprosy	0.00107	0.00324	CcSEcCtD
Bexarotene—Sweating—Thalidomide—leprosy	0.00105	0.00319	CcSEcCtD
Bexarotene—Haematuria—Thalidomide—leprosy	0.00105	0.00318	CcSEcCtD
Bexarotene—Epistaxis—Thalidomide—leprosy	0.00103	0.00314	CcSEcCtD
Bexarotene—Sinusitis—Thalidomide—leprosy	0.00103	0.00313	CcSEcCtD
Bexarotene—Rhinitis—Thalidomide—leprosy	0.000987	0.003	CcSEcCtD
Bexarotene—Hypoaesthesia—Thalidomide—leprosy	0.000979	0.00298	CcSEcCtD
Bexarotene—Pharyngitis—Thalidomide—leprosy	0.000977	0.00297	CcSEcCtD
Bexarotene—Urinary tract disorder—Thalidomide—leprosy	0.000972	0.00295	CcSEcCtD
Bexarotene—Oedema peripheral—Thalidomide—leprosy	0.00097	0.00295	CcSEcCtD
Bexarotene—Urethral disorder—Thalidomide—leprosy	0.000965	0.00293	CcSEcCtD
Bexarotene—Eye disorder—Thalidomide—leprosy	0.00092	0.0028	CcSEcCtD
Bexarotene—Tinnitus—Thalidomide—leprosy	0.000918	0.00279	CcSEcCtD
Bexarotene—Cardiac disorder—Thalidomide—leprosy	0.000914	0.00278	CcSEcCtD
Bexarotene—Angiopathy—Thalidomide—leprosy	0.000893	0.00271	CcSEcCtD
Bexarotene—Chills—Thalidomide—leprosy	0.000883	0.00268	CcSEcCtD
Bexarotene—Arrhythmia—Thalidomide—leprosy	0.000879	0.00267	CcSEcCtD
Bexarotene—Alopecia—Thalidomide—leprosy	0.00087	0.00264	CcSEcCtD
Bexarotene—Vomiting—Dapsone—leprosy	0.000869	0.00264	CcSEcCtD
Bexarotene—Malnutrition—Thalidomide—leprosy	0.000857	0.0026	CcSEcCtD
Bexarotene—Headache—Dapsone—leprosy	0.000856	0.0026	CcSEcCtD
Bexarotene—Flatulence—Thalidomide—leprosy	0.000844	0.00257	CcSEcCtD
Bexarotene—Tension—Thalidomide—leprosy	0.000841	0.00255	CcSEcCtD
Bexarotene—Dysgeusia—Thalidomide—leprosy	0.000839	0.00255	CcSEcCtD
Bexarotene—Nervousness—Thalidomide—leprosy	0.000832	0.00253	CcSEcCtD
Bexarotene—Back pain—Thalidomide—leprosy	0.000829	0.00252	CcSEcCtD
Bexarotene—Muscle spasms—Thalidomide—leprosy	0.000824	0.0025	CcSEcCtD
Bexarotene—Nausea—Dapsone—leprosy	0.000811	0.00247	CcSEcCtD
Bexarotene—Ill-defined disorder—Thalidomide—leprosy	0.000795	0.00242	CcSEcCtD
Bexarotene—Anaemia—Thalidomide—leprosy	0.000792	0.00241	CcSEcCtD
Bexarotene—Agitation—Thalidomide—leprosy	0.000787	0.00239	CcSEcCtD
Bexarotene—Malaise—Thalidomide—leprosy	0.000773	0.00235	CcSEcCtD
Bexarotene—Vertigo—Thalidomide—leprosy	0.00077	0.00234	CcSEcCtD
Bexarotene—Syncope—Thalidomide—leprosy	0.000768	0.00233	CcSEcCtD
Bexarotene—Leukopenia—Thalidomide—leprosy	0.000767	0.00233	CcSEcCtD
Bexarotene—Palpitations—Thalidomide—leprosy	0.000757	0.0023	CcSEcCtD
Bexarotene—Loss of consciousness—Thalidomide—leprosy	0.000753	0.00229	CcSEcCtD
Bexarotene—Cough—Thalidomide—leprosy	0.000748	0.00227	CcSEcCtD
Bexarotene—Hypertension—Thalidomide—leprosy	0.00074	0.00225	CcSEcCtD
Bexarotene—Chest pain—Thalidomide—leprosy	0.000729	0.00222	CcSEcCtD
Bexarotene—Myalgia—Thalidomide—leprosy	0.000729	0.00222	CcSEcCtD
Bexarotene—Arthralgia—Thalidomide—leprosy	0.000729	0.00222	CcSEcCtD
Bexarotene—Anxiety—Thalidomide—leprosy	0.000727	0.00221	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000724	0.0022	CcSEcCtD
Bexarotene—Discomfort—Thalidomide—leprosy	0.000721	0.00219	CcSEcCtD
Bexarotene—Dry mouth—Thalidomide—leprosy	0.000713	0.00217	CcSEcCtD
Bexarotene—Confusional state—Thalidomide—leprosy	0.000705	0.00214	CcSEcCtD
Bexarotene—Oedema—Thalidomide—leprosy	0.000699	0.00212	CcSEcCtD
Bexarotene—Infection—Thalidomide—leprosy	0.000695	0.00211	CcSEcCtD
Bexarotene—Shock—Thalidomide—leprosy	0.000688	0.00209	CcSEcCtD
Bexarotene—Nervous system disorder—Thalidomide—leprosy	0.000686	0.00208	CcSEcCtD
Bexarotene—Thrombocytopenia—Thalidomide—leprosy	0.000685	0.00208	CcSEcCtD
Bexarotene—Tachycardia—Thalidomide—leprosy	0.000683	0.00207	CcSEcCtD
Bexarotene—Skin disorder—Thalidomide—leprosy	0.000679	0.00206	CcSEcCtD
Bexarotene—Hyperhidrosis—Thalidomide—leprosy	0.000676	0.00205	CcSEcCtD
Bexarotene—Anorexia—Thalidomide—leprosy	0.000667	0.00203	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Thalidomide—leprosy	0.000637	0.00194	CcSEcCtD
Bexarotene—Insomnia—Thalidomide—leprosy	0.000633	0.00192	CcSEcCtD
Bexarotene—Paraesthesia—Thalidomide—leprosy	0.000628	0.00191	CcSEcCtD
Bexarotene—Dyspnoea—Thalidomide—leprosy	0.000623	0.00189	CcSEcCtD
Bexarotene—Somnolence—Thalidomide—leprosy	0.000622	0.00189	CcSEcCtD
Bexarotene—Dyspepsia—Thalidomide—leprosy	0.000616	0.00187	CcSEcCtD
Bexarotene—Decreased appetite—Thalidomide—leprosy	0.000608	0.00185	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Thalidomide—leprosy	0.000604	0.00183	CcSEcCtD
Bexarotene—Fatigue—Thalidomide—leprosy	0.000603	0.00183	CcSEcCtD
Bexarotene—Pain—Thalidomide—leprosy	0.000598	0.00182	CcSEcCtD
Bexarotene—Constipation—Thalidomide—leprosy	0.000598	0.00182	CcSEcCtD
Bexarotene—Feeling abnormal—Thalidomide—leprosy	0.000576	0.00175	CcSEcCtD
Bexarotene—Gastrointestinal pain—Thalidomide—leprosy	0.000572	0.00174	CcSEcCtD
Bexarotene—Abdominal pain—Thalidomide—leprosy	0.000553	0.00168	CcSEcCtD
Bexarotene—Body temperature increased—Thalidomide—leprosy	0.000553	0.00168	CcSEcCtD
Bexarotene—Hypersensitivity—Thalidomide—leprosy	0.000515	0.00157	CcSEcCtD
Bexarotene—Asthenia—Thalidomide—leprosy	0.000502	0.00152	CcSEcCtD
Bexarotene—Pruritus—Thalidomide—leprosy	0.000495	0.0015	CcSEcCtD
Bexarotene—Diarrhoea—Thalidomide—leprosy	0.000478	0.00145	CcSEcCtD
Bexarotene—Dizziness—Thalidomide—leprosy	0.000462	0.00141	CcSEcCtD
Bexarotene—Vomiting—Thalidomide—leprosy	0.000445	0.00135	CcSEcCtD
Bexarotene—Rash—Thalidomide—leprosy	0.000441	0.00134	CcSEcCtD
Bexarotene—Dermatitis—Thalidomide—leprosy	0.000441	0.00134	CcSEcCtD
Bexarotene—Headache—Thalidomide—leprosy	0.000438	0.00133	CcSEcCtD
Bexarotene—Nausea—Thalidomide—leprosy	0.000415	0.00126	CcSEcCtD
